Your session is about to expire
← Back to Search
Antibiotic Therapy for Pseudomyxoma Peritonei
Study Summary
This trial will study whether antibiotic therapy can improve the disease progression and overall survival for patients with Pseudomyxoma Peritonei.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential risks have been linked to the PrevPac (Prevacid, Amoxicillin, Clarithromycin) medication?
"Our team at Power has assigned a rating of 2 to PrevPac (Prevacid, Amoxicillin, Clarithromycin) due to its Phase 2 trial status. This implies that there is data confirming the treatment's safety but not yet any evidence for its efficacy."
Is enrollment still possible for this trial?
"The information published on clinicaltrials.gov suggests that this trial has ceased recruitment for participants, with the original posting taking place on January 1st 2015 and the last update occurring on August 30th 2022. While no longer seeking patients, there are 101 other trials open to enrollment at this time."
What clinical condition is the PrevPac (Prevacid, Amoxicillin, Clarithromycin) prescription regimen most commonly prescribed for?
"PrevPac, a combination of Prevacid, Amoxicillin and Clarithromycin, can be employed to combat mycobacterial infection, lower respiratory tract infections (lrti), as well as nsaid use."
How many patients have been enrolled in this clinical experiment?
"This clinical trial is no longer enrolling participants. It was first uploaded on January 1st 2015, and its most recent update occurred in August of 2022. If you are seeking alternate studies, there are currently 22 trials for pseudomyxoma peritonei that have open enrollment as well as 79 research projects looking to recruit patients using PrevPac (Prevacid, Amoxicillin, Clarithromycin)."
Share this study with friends
Copy Link
Messenger